NL-OMON50995
Completed
Not Applicable
A randomized, double-blind, placebo-controlled 5-way crossover study to assess the modulating effect of single doses of CBD on psychotropic and analgesic effects of a single dose of THC in healthy volunteers using the NeuroCart and PainCart test batteries. - THC&CBD NeuroCart&PainCart study
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Not specified
- Sponsor
- Centre for Human Drug Research
- Enrollment
- 30
- Status
- Completed
- Last Updated
- last year
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •1\. Signed informed consent prior to any study\-mandated procedure.
- •2\. Healthy male or female subjects, 18 to 45 years of age, inclusive at
- •3\. Body mass index (BMI) between 18 and 30 kg/m2, inclusive at screening, and
- •with a minimum weight of 50 kg.
- •4\. All women of childbearing potential and all males must practice effective
- •contraception during the study and be willing and able to continue
- •contraception for at least 90 days after their last dose of study treatment.
- •5\. Has the ability to communicate well with the Investigator in the Dutch
- •language and willing to comply with the study restrictions.
- •6\. Subject is familiar with cannabis use for at least one year. In the previous
Exclusion Criteria
- •1\. Evidence of any active or chronic disease or condition that could interfere
- •with, or for which the treatment of might interfere with, the conduct of the
- •study, or that would pose an unacceptable risk to the subject in the opinion of
- •the investigator (following a detailed medical history, physical examination,
- •vital signs (systolic and diastolic blood pressure, pulse rate, body
- •temperature) and 12\-lead electrocardiogram (ECG)). Minor deviations from the
- •normal range may be accepted, if judged by the Investigator to have no clinical
- •2\. Clinically significant abnormalities, as judged by the investigator, in
- •laboratory test results (including hepatic and renal panels, complete blood
- •count, chemistry panel and urinalysis). In the case of uncertain or
Outcomes
Primary Outcomes
Not specified
Similar Trials
Active, not recruiting
Not Applicable
A randomised, single blind, placebo-controlled 5-way crossover trial of single doses of intranasal GSK256066 in subjects with seasonal allergic rhinitis (SAR)EUCTR2006-006710-15-DEGlaxoSmithKline Research & Development Limited
Completed
Not Applicable
An Efficacy and Safety Study of Azilsartan Medoxomil Compared to Valsartan and Olmesartan in Participants With Essential Hypertension.-I10 Essential (primary) hypertensionEssential (primary) hypertensionI10PER-073-08TAKEDA GLOBAL RESEARCH & DEVELOPMENT CENTER, INC.,
Active, not recruiting
Not Applicable
A Double-blind Confirmatory Trial of Levetiracetam in Epilepsy Patients With Partial Onset SeizuresEUCTR2014-004333-57-Outside-EU/EEACB Japan Co., Ltd.352
Completed
Not Applicable
A double-blind, placebo-controlled, five-way partial crossover study with EVP-6124 and donepezil in the scopolamine challenge model in healthy elderly volunteersAlzheimer's Diseasedementia10057167NL-OMON37445EnVivo Pharmaceuticals36
Recruiting
Phase 1
THC for chronic neuropathic paiChronic neuropathic painMedDRA version: 21.0Level: LLTClassification code: 10054095Term: Neuropathic pain Class: 10029205Therapeutic area: Diseases [C] - Nervous System Diseases [C10]CTIS2022-502343-35-00Centre For Human Drug Research200